孟鲁司特钠和草分枝杆菌F.U.36治疗婴幼儿哮喘的研究

Study of montelukast sodium and mycobacterium phlei F.U.36 on asthma infant

目的 探讨孟鲁司特钠和草分枝杆菌F .U .36联合治疗婴幼儿哮喘的疗效。方法 将 96例非急性发作期哮喘患儿随机分为 3组 ,治疗Ⅰ组给予孟鲁司特钠联合草分枝杆菌F .U .36治疗 ,治疗Ⅱ组仅予孟鲁司特钠 ,对照组予常规止咳、平喘及必要的抗感染治疗。哮喘急性发作期均予糖皮质激素及 β2 激动剂等强化治疗。结果 治疗 12周后 ,治疗Ⅰ组、治疗Ⅱ组多项哮喘控制参数明显改善 ,与对照组比较有非常显著性差异 (P均 <0 .0 1) ,且Ⅰ组明显优于Ⅱ组 (P <0 .0 1或 0 .0 5 )。结论 孟鲁司特钠和草分枝杆菌F .U .

Objective It is to evaluate the efficacy of the combination of montelukast sodium and mycobacterium phlei F.U.36 on asthma infant. Methods ninety six asthma infant were randomly divided into three groups. Group Ⅰ were treated with montelukast sodium and mycobacterium phlei F.U.36, group Ⅱ were treated with montelukast sodium and group Ⅲ were routinely treated with antitussive, anti asthmatic and anti infective drugs. Glucocorticoid and β 2-receptor excitomotor were added when the infants were in acute paroxysmal term of asthma. Results Several indexes of asthma in group Ⅰ and group Ⅱ were more improved than those in control group, there were significant difference ( P <0.01). And those in group Ⅰ were prior to those in group Ⅱ ( P <0.05). Conclusion The combination of montelukast sodium and mycobacterium phlei F.U.36 is effective on asthma infant.